{"id":"ticagrelor","brandName":"Brilinta","genericName":"ticagrelor","companyId":"astrazeneca","companyName":"AstraZeneca","phase":"marketed","status":"active","modality":"","aliases":[],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"","enrichmentLevel":3,"visitCount":1,"mechanism":{"target":"Equilibrative nucleoside transporter 1, P2Y purinoceptor 12, P2Y purinoceptor 12","drugClass":"P2Y12 Platelet Inhibitor [EPC]"},"administration":{"route":"Oral"},"safety":{"boxedWarnings":["WARNING: BLEEDING RISK • Ticagrelor, like other antiplatelet agents, can cause significant, sometimes fatal bleeding ( 5.1 , 6.1 ). • Do not use ticagrelor tablets in patients with active pathological bleeding or a history of intracranial hemorrhage (4.1 , 4.2 ). •Do not start ticagrelor tablets in patients undergoing urgent coronary artery bypass graft surgery (CABG) ( 5.1 , 6.1 ). • If possible, manage bleeding without discontinuing ticagrelor tablets. Stopping ticagrelor tablets increases the risk of subsequent cardiovascular events ( 5.2 ). WARNING: BLEEDING RISK See full prescribing information for complete boxed warning. • Ticagrelor, like other antiplatelet agents, can cause significant, sometimes fatal bleeding. ( 5.1 , 6.1 ) • Do not use ticagrelor tablets in patients with active pathological bleeding or a history of intracranial hemorrhage. ( 4.1 , 4.2 ) • Do not start ticagrelor tablets in patients undergoing urgent coronary artery bypass graft surgery(CABG). ( 5.1 , 6.1 ) • If possible, manage bleeding without discontinuing ticagrelor tablets. Stopping ticagrelor tablets increases the risk of subsequent cardiovascular events. ( 5.2 )"],"safetySignals":[{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"3953 reports"},{"date":"","signal":"MYOCARDIAL INFARCTION","source":"FDA FAERS","actionTaken":"2741 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"1714 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"1525 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"1502 reports"},{"date":"","signal":"CHEST PAIN","source":"FDA FAERS","actionTaken":"1445 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"1224 reports"},{"date":"","signal":"CONTUSION","source":"FDA FAERS","actionTaken":"1066 reports"},{"date":"","signal":"DRUG INTERACTION","source":"FDA FAERS","actionTaken":"929 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"909 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Bleeding (non-CABG major)","drugRate":"","severity":"common","organSystem":""},{"effect":"Dyspnea","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Disease of liver","Hepatic failure","Intracranial hemorrhage","Significant Bleeding","Surgical procedure"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Fatal bleeding","drugRate":"","severity":"serious"},{"effect":"Intracranial bleeding","drugRate":"","severity":"serious"},{"effect":"Intrapericardial bleeding with cardiac tamponade","drugRate":"","severity":"serious"},{"effect":"Hypovolemic shock or severe hypotension","drugRate":"","severity":"serious"},{"effect":"Major bleeding (life-threatening)","drugRate":"","severity":"serious"},{"effect":"CABG-related bleeding","drugRate":"","severity":"serious"}]},"trials":["NCT04023630","NCT03161002","NCT01812200","NCT05474053","NCT02247128","NCT01967615","NCT03489863","NCT06554821","NCT02798874","NCT02939235","NCT06853535","NCT04483583","NCT02264912","NCT05122741","NCT04937699","NCT04695106","NCT05773989","NCT03679091","NCT05746416","NCT04501900","NCT03492931","NCT02070653","NCT03251859","NCT03372785","NCT02224066","NCT02271022","NCT03184805","NCT04744571","NCT02435563","NCT05907629","NCT02942550","NCT03823547","NCT06826144","NCT03729401","NCT04307511","NCT02044146","NCT02303717","NCT02032290","NCT01701453","NCT01795820","NCT03551964","NCT02400333","NCT03577652","NCT07432516","NCT02217878","NCT04734353","NCT03354429","NCT05162131","NCT02317198","NCT05166538"],"indications":{"approved":[{"name":"Acute coronary syndrome","diseaseId":"acute-coronary-syndrome","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Myocardial Reinfarction Prevention","diseaseId":"myocardial-reinfarction-prevention","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Percutaneous coronary intervention","diseaseId":"percutaneous-coronary-intervention","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Peripheral vascular disease","diseaseId":"peripheral-vascular-disease","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"commercial":{"revenueYear":2024,"annualRevenue":1100,"revenueSource":"Verified: AstraZeneca AR","revenueCurrency":"USD","revenueConfidence":"verified"},"patents":[{"type":"Method of Use","number":"10300065","applicant":"ASTRAZENECA PHARMACEUTICALS LP","territory":"US","tradeName":"BRILINTA","expiryDate":"2036-01-27"},{"type":"Formulation","number":"8425934","applicant":"ASTRAZENECA PHARMACEUTICALS LP","territory":"US","tradeName":"BRILINTA","expiryDate":"2030-04-17"},{"type":"Compound","number":"8425934*PED","applicant":"ASTRAZENECA PHARMACEUTICALS LP","territory":"US","tradeName":"BRILINTA","expiryDate":"2030-10-17"},{"type":"Compound","number":"10300065*PED","applicant":"ASTRAZENECA PHARMACEUTICALS LP","territory":"US","tradeName":"BRILINTA","expiryDate":"2036-07-27"}],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[{"nctId":"NCT04023630","phase":"Phase 4","title":"An Open-label, Randomized, Controlled, Multicenter Study to Evaluate DUAL Antithrombotic Therapy With Rivaroxaban Plus Ticagrelor vs. Rivaroxaban Plus Clopidogrel in Patients With Atrial Fibrillation ","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","isPivotal":false,"enrollment":4000,"indication":"Atrial Fibrillation, Acute Coronary Syndromes","completionDate":"2021-09-30"},{"nctId":"NCT03161002","phase":"N/A","title":"Impact of Biomarkers on Pharmacokinetics and Pharmacodynamics of Ticagrelor","status":"UNKNOWN","sponsor":"Cui Yimin","isPivotal":false,"enrollment":400,"indication":"Ticagrelor, Pharmacokinetics","completionDate":"2021-12"},{"nctId":"NCT01812200","phase":"Phase 4","title":"A Prospective, Randomized, Controlled, Analyst-blinded, Parallel Group Study to Investigate the Effect of Antithrombotic Triple Therapy With Ticagrelor and Acetylsalicylic Acid in Combination With Dab","status":"COMPLETED","sponsor":"Medical University of Vienna","isPivotal":false,"enrollment":60,"indication":"Atrial Fibrillation, Acute Coronary Syndrome","completionDate":"2013-07"},{"nctId":"NCT05474053","phase":"Phase 3","title":"Testing P2Y12 Platelet Inhibitors Generics Beyond Bioequivalence: A Parallel Single-blinded Randomized Trial","status":"COMPLETED","sponsor":"Cairo University","isPivotal":true,"enrollment":29,"indication":"Cardiovascular Diseases, Acute Coronary Syndrome","completionDate":"2021-11-28"},{"nctId":"NCT02247128","phase":"Phase 4","title":"Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation","status":"COMPLETED","sponsor":"St. Antonius Hospital","isPivotal":false,"enrollment":1016,"indication":"Aortic Valve Disease, Myocardial Infarction","completionDate":"2020-04"},{"nctId":"NCT01967615","phase":"N/A","title":"P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry","status":"COMPLETED","sponsor":"G. d'Annunzio University","isPivotal":false,"enrollment":4500,"indication":"Coronary Arteriosclerosis","completionDate":"2017-04"},{"nctId":"NCT03489863","phase":"Phase 4","title":"Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function Genotype: a Validation Study in Patients With Stable Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","isPivotal":false,"enrollment":14,"indication":"Coronary Artery Disease","completionDate":"2019-03-20"},{"nctId":"NCT06554821","phase":"Phase 1","title":"An Open-label, Randomised, Parallel-group, Fixed-sequence Study to Assess the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":false,"enrollment":28,"indication":"Healthy Participants","completionDate":"2024-10-08"},{"nctId":"NCT02798874","phase":"NA","title":"Chinese People's Liberation Army General Hospital","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","isPivotal":false,"enrollment":240,"indication":"Cardiovascular Diseases","completionDate":"2016-12"},{"nctId":"NCT02939235","phase":"Phase 4","title":"Differences in the Pharmacokinetic and Pharmacodynamic Profile of Ticagrelor and Its Active Metabolite AR-C124900XX Between Patients With Unstable Angina Pectoris Treated With Crushed Ticagrelor and a","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","isPivotal":false,"enrollment":32,"indication":"Unstable Angina Pectoris","completionDate":"2017-12"},{"nctId":"NCT06853535","phase":"Phase 3","title":"Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE","status":"RECRUITING","sponsor":"Sichuan Provincial People's Hospital","isPivotal":true,"enrollment":5138,"indication":"Acute Ischemic Stroke, Clopidogrel Resistance","completionDate":"2027-12-31"},{"nctId":"NCT04483583","phase":"Phase 4","title":"Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After Undergoing Percutaneous Coronary Intervention:The Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) - 2 S","status":"COMPLETED","sponsor":"University of Florida","isPivotal":false,"enrollment":81,"indication":"Coronary Artery Disease","completionDate":"2025-01-07"},{"nctId":"NCT02264912","phase":"N/A","title":"The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry","status":"COMPLETED","sponsor":"Faculty Hospital Kralovske Vinohrady","isPivotal":false,"enrollment":2016,"indication":"Platelet Aggregation Onhibitors","completionDate":"2018-07"},{"nctId":"NCT05122741","phase":"N/A","title":"Modulation of the WNT/Beta-Catenin Pathway in Patients With Acute Myocardial Infarction","status":"UNKNOWN","sponsor":"University of Messina","isPivotal":false,"enrollment":50,"indication":"Myocardial Infarction, Myocardial Fibrosis","completionDate":"2023-12-31"},{"nctId":"NCT04937699","phase":"Phase 4","title":"Efficacy and Safety of Sequential Monotherapy of Ticagrelor and Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention With Acute Coronary Syndrome","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","isPivotal":false,"enrollment":2690,"indication":"Acute Coronary Syndrome, Percutaneous Coronary Intervention","completionDate":"2026-12-31"},{"nctId":"NCT04695106","phase":"Phase 4","title":"Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With Acute Coronary Syndrome and Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention (ADONIS-PCI)","status":"UNKNOWN","sponsor":"Medical University of Gdansk","isPivotal":false,"enrollment":2230,"indication":"Atrial Fibrillation, Antithrombotic Therapy","completionDate":"2026-03-31"},{"nctId":"NCT05773989","phase":"Phase 4","title":"Pharmacodynamic Outcomes in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Treated With an Individualized Treatment STRATEGY","status":"UNKNOWN","sponsor":"St. Antonius Hospital","isPivotal":false,"enrollment":88,"indication":"Coronary Artery Disease, Platelet Reactivity","completionDate":"2025-05-01"},{"nctId":"NCT03679091","phase":"Phase 4","title":"Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable Coronary Artery Disease: a Randomized, Single-blind, Crossover Clinical Study","status":"COMPLETED","sponsor":"First Affiliated Hospital of Harbin Medical University","isPivotal":false,"enrollment":36,"indication":"Platelet Reactivity","completionDate":"2019-02-28"},{"nctId":"NCT05746416","phase":"N/A","title":"Xience Registry Study for the Impact of Early Use of Low-Dose Ticagrelor-Based Dual Antiplatelet Therapy to Clinical Outcomes in Patient Undergoing Percutaneous Coronary Interventions for Complex Lesi","status":"COMPLETED","sponsor":"Hanyang University Seoul Hospital","isPivotal":false,"enrollment":977,"indication":"Coronary Artery Disease, Percutaneous Coronary Intervention","completionDate":"2021-12-31"},{"nctId":"NCT04501900","phase":"Phase 4","title":"The Standard Versus Prolonged Dual Antiplatelet Therapy After the XINSORB Bioresorbable Scaffold Implantation Trial","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","isPivotal":false,"enrollment":2106,"indication":"Cardiovascular Diseases","completionDate":"2026-04"},{"nctId":"NCT03492931","phase":"Phase 1","title":"A Multi-centre, Phase I, Open-label, Single-dose Study to Investigate Pharmacokinetics (PK) of Ticagrelor in Infants and Toddlers, Aged 0 to Less Than 24 Months, With Sickle Cell Disease (HESTIA4)","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":false,"enrollment":21,"indication":"Sickle Cell Disease","completionDate":"2019-05-07"},{"nctId":"NCT02070653","phase":"Phase 2","title":"Does Ticagrelor Inhibit Growth of Small Abdominal Aortic Aneurysms? A Randomised Controlled Trial (TicAAA)","status":"COMPLETED","sponsor":"Uppsala University","isPivotal":false,"enrollment":145,"indication":"Abdominal Aortic Aneurysm","completionDate":"2017-07"},{"nctId":"NCT03251859","phase":"Phase 3","title":"A Randomized, Open-label, Pharmacodynamic and Pharmacokinetic Trial Assessing the Effect of Lowering Ticagrelor Maintenance Dose Early After Myocardial Infarction on Platelet Inhibition (ELECTRA Pilot","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","isPivotal":true,"enrollment":52,"indication":"Myocardial Infarction","completionDate":"2018-02-23"},{"nctId":"NCT03372785","phase":"N/A","title":"The Success of Opening Concurrent Chronic Total Occlusion leSion to Improve Cardiac Function Trial in Patients With Multi-vessel Disease (SOS-moral): Study Protocol of a Prospective Multicenter Study","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","isPivotal":false,"enrollment":240,"indication":"Chronic Total Occlusion of Coronary Artery, Percutaneous Coronary Intervention","completionDate":"2022-04"},{"nctId":"NCT02224066","phase":"Phase 4","title":"Assessment of Platelet REACtivity After Transcatheter Aortic Valve Implantation","status":"COMPLETED","sponsor":"Hospital de Meixoeiro","isPivotal":false,"enrollment":65,"indication":"Severe Aortic Valve Stenosis, Transcatheter Aortic Valve Implantation","completionDate":"2018-08"},{"nctId":"NCT02271022","phase":"N/A","title":"Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":false,"enrollment":2000,"indication":"Acute Coronary Syndromes","completionDate":"2019-10-31"},{"nctId":"NCT03184805","phase":"NA","title":"Randomized Controlled Comparison: STOPping Versus Continuing Antiplatelet Therapy During Noncardiac Surgery and Procedures After Next Generation Drug-eluting Stent Implantation (STOP-ASP Trial)","status":"TERMINATED","sponsor":"Yonsei University","isPivotal":false,"enrollment":140,"indication":"Coronary Artery Disease","completionDate":"2018-04-09"},{"nctId":"NCT04744571","phase":"NA","title":"Safety and Efficacy of Drug-Coated Balloon Angioplasty for the Treatment of Chronic Total Occlusions","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","isPivotal":false,"enrollment":200,"indication":"Coronary Artery Disease, Coronary Occlusion","completionDate":"2023-01"},{"nctId":"NCT02435563","phase":"Phase 2","title":"Dose Adaptation to Offset the Pharmacokinetic Interaction Between Ticagrelor and Ritonavir in Healthy Volunteers by Population-based PK Modeling (Simcyp®)","status":"COMPLETED","sponsor":"University Hospital, Geneva","isPivotal":false,"enrollment":22,"indication":"Healthy","completionDate":"2015-04"},{"nctId":"NCT05907629","phase":"N/A","title":"Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging","status":"RECRUITING","sponsor":"Yale University","isPivotal":false,"enrollment":300,"indication":"Stroke, Intracranial Atherosclerotic Stenosis (ICAS)","completionDate":"2029-03-31"},{"nctId":"NCT02942550","phase":"Phase 4","title":"Methylnaltrexone as a Method to imprOVE Platelet Inhibition of Ticagrelor in Morphine-treated Patients With ST-segMENT Elevation Myocardial Infarction: a Prospective, Single Blinded Randomized, Placeb","status":"COMPLETED","sponsor":"Karolinska University Hospital","isPivotal":false,"enrollment":82,"indication":"STEMI, Morphine","completionDate":"2017-12"},{"nctId":"NCT03823547","phase":"N/A","title":"Future Optimal Research and Care Evaluation: On the Way to \"Personalized Medicine\" With an Ongoing Registry of Patients in Daily Clinical Practice (Hart Beter/ FORCE-ACS)","status":"RECRUITING","sponsor":"J.M. ten Berg","isPivotal":false,"enrollment":99999,"indication":"Acute Coronary Syndrome, Myocardial Infarction","completionDate":"2050-06-30"},{"nctId":"NCT06826144","phase":"NA","title":"Chronic Remote Ischemic Conditioning in Small Infarctions Associated with Stent-assisted Coiling of Unruptured Intracranial Aneurysms: a Single-center Randomized Controlled Trial.","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","isPivotal":false,"enrollment":84,"indication":"Unruptured Intracranial Aneurysm, Infarction Cerebral","completionDate":"2026-06-01"},{"nctId":"NCT03729401","phase":"Phase 4","title":"Personalization of Long-Term Antiplatelet Therapy Using a Novel Combined Demographic/Pharmacogenomic Strategy - the RAPID EXTEND Randomized Study","status":"SUSPENDED","sponsor":"Ottawa Heart Institute Research Corporation","isPivotal":false,"enrollment":390,"indication":"Coronary Artery Disease, Myocardial Infarction","completionDate":"2026-09"},{"nctId":"NCT04307511","phase":"Phase 4","title":"A Randomized Controlled sTudy of Low Dose vs Standard Dose of tIcaGrelor on Platelet Function After intErvention for Acute Coronary syndRome in Diabetes Mellitus Patients","status":"RECRUITING","sponsor":"Shanghai Tong Ren Hospital","isPivotal":false,"enrollment":40,"indication":"Acute Coronary Syndrome Patients With Diabetes After PCI","completionDate":"2024-05-31"},{"nctId":"NCT02044146","phase":"Phase 2","title":"Reassessment of Anti-Platelet Therapy Using InDividualized Strategies - Modifying Acute CoroNary Syndrome Algorithms Based on Genetic and Demographic Evaluation: The RAPID-MANAGE Study","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","isPivotal":true,"enrollment":120,"indication":"Acute Coronary Syndrome, Percutaneous Coronary Intervention","completionDate":"2017-06"},{"nctId":"NCT02303717","phase":"NA","title":"Improved Drug Eluting Stent for Percutaneous Coronary Intervention of the Left Main Artery in a Real World All-comers Population","status":"UNKNOWN","sponsor":"NHS National Waiting Times Centre Board","isPivotal":false,"enrollment":818,"indication":"Coronary Artery Disease","completionDate":"2020-12"},{"nctId":"NCT02032290","phase":"Phase 4","title":"","status":"UNKNOWN","sponsor":"Azienda Policlinico Umberto I","isPivotal":false,"enrollment":88,"indication":"Acute Coronary Syndrome:, Non ST Elevation Myocardial Infarction","completionDate":""},{"nctId":"NCT01701453","phase":"NA","title":"Smart Angioplasty Research Team: Safety of 6-month Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes (SMART-DATE)","status":"UNKNOWN","sponsor":"Samsung Medical Center","isPivotal":false,"enrollment":2712,"indication":"Acute Coronary Syndrome","completionDate":"2019-11"},{"nctId":"NCT01795820","phase":"NA","title":"Platelet Aggregation During Pharmacological Shift From Clopidogrel to Ticagrelor in Patients With Acute Coronary Syndrome","status":"COMPLETED","sponsor":"University Magna Graecia","isPivotal":false,"enrollment":50,"indication":"Acute Coronary Syndrome","completionDate":""},{"nctId":"NCT03551964","phase":"Phase 4","title":"Cangrelor Versus Ticagrelor In Patients With Acute Myocardial Infarction Complicated With Initial Cardiogenic Shock","status":"COMPLETED","sponsor":"Faculty Hospital Kralovske Vinohrady","isPivotal":false,"enrollment":605,"indication":"Acute Myocardial Infarction, Cardiogenic Shock","completionDate":"2025-04-01"},{"nctId":"NCT02400333","phase":"Phase 1","title":"An Open-label, Randomised, Four-period, Four-treatment, Crossover, Single-centre, Single-dose Study to Assess the Bioavailability of Ticagrelor Orodispersible Tablets, Compared to Ticagrelor Immediate","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":false,"enrollment":100,"indication":"Bioavailability, Healthy Subjects","completionDate":"2015-07"},{"nctId":"NCT03577652","phase":"NA","title":"The Optimal Strategy of Switching From Clopidogrel to Ticagrelor in Patients With Complexity of Coronary Artery Disease","status":"COMPLETED","sponsor":"Shenyang Northern Hospital","isPivotal":false,"enrollment":108,"indication":"Coronary Artery Disease, Ticagrelor","completionDate":"2018-01-10"},{"nctId":"NCT07432516","phase":"NA","title":"OPtimal Medical Strategy for Patients With Acute Coronary Syndrome Treated With Drug-eluting Stents: Enhancing Outcomes With antiPlatelet and Lipid-lowering Therapy (OPACT Trial)","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","isPivotal":false,"enrollment":4400,"indication":"Coronary Artery Disease","completionDate":"2033-06"},{"nctId":"NCT02217878","phase":"Phase 4","title":"A Randomized, Double-blind Study Evaluating the Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor and Its Active Metabolite (AR-C124910XX) in Patients With ST-segment Elevat","status":"COMPLETED","sponsor":"Collegium Medicum w Bydgoszczy","isPivotal":false,"enrollment":74,"indication":"ST-segment Elevation Myocardial Infarction, Non-ST-segment Elevation Myocardial Infarction","completionDate":"2015-06"},{"nctId":"NCT04734353","phase":"Phase 4","title":"Efficacy, Safety and Tolerability of PrasugrEl 5mg or TIcagrelor 60mg in COmplex and Higher-Risk Indicated PCI/PatieNts: The Prospective, Randomized, Open-labeled, Blinded Endpoint (PROBE), Multi-cent","status":"UNKNOWN","sponsor":"Gyeongsang National University Hospital","isPivotal":false,"enrollment":492,"indication":"Coronary Artery Disease","completionDate":"2022-06-15"},{"nctId":"NCT03354429","phase":"Phase 3","title":"A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke a","status":"COMPLETED","sponsor":"AstraZeneca","isPivotal":true,"enrollment":11016,"indication":"Acute Ischaemic Stroke, Transient Ischaemic Attack","completionDate":"2019-12-13"},{"nctId":"NCT05162131","phase":"Phase 1","title":"A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PB2452 (Bentracimab) With and Witho","status":"TERMINATED","sponsor":"SFJ Pharmaceuticals, Inc.","isPivotal":false,"enrollment":34,"indication":"Healthy","completionDate":"2022-12-30"},{"nctId":"NCT02317198","phase":"Phase 4","title":"Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly","status":"COMPLETED","sponsor":"St. Antonius Hospital","isPivotal":false,"enrollment":1011,"indication":"Non-ST-elevation Acute Coronary Syndrome, Unstable Angina","completionDate":"2019-11"},{"nctId":"NCT05166538","phase":"Phase 4","title":"Dual Antiplatelet Therapy in Patients With Clopidogrel Resistance Following Off-Pump Coronary Artery Bypass: Prospective, Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Yonsei University","isPivotal":false,"enrollment":204,"indication":"Multi Vessel Coronary Artery Disease","completionDate":"2023-12"}],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2014-03-07T00:00:00.000Z","mah":"ASTRAZENECA","brand_name_local":null,"application_number":"NDA022433"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-09-04T00:00:00.000Z","mah":"WATSON LABS INC","brand_name_local":null,"application_number":"ANDA208390"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-04-15T00:00:00.000Z","mah":"SUNSHINE","brand_name_local":null,"application_number":"ANDA208508"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-10-28T00:00:00.000Z","mah":"ALKEM LABS LTD","brand_name_local":null,"application_number":"ANDA210219"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2025-10-28T00:00:00.000Z","mah":"MACLEODS PHARMS LTD","brand_name_local":null,"application_number":"ANDA212258"},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":"EMEA/H/C/001241"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Brilique","application_number":null}],"patentsNormalised":[{"patent_number":"8425934","territory":"US","patent_type":"Formulation","expiry_date":"2030-04-17T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8425934*PED","territory":"US","patent_type":"Compound","expiry_date":"2030-10-17T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10300065","territory":"US","patent_type":"Method of Use","expiry_date":"2036-01-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10300065*PED","territory":"US","patent_type":"Compound","expiry_date":"2036-07-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":8,"withResults":5},"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=ticagrelor","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:17:51.275036+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T01:17:51.274706+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:17:57.916316+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T01:17:49.902799+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ticagrelor","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:17:58.679401+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:17:48.403855+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:17:48.403920+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (boxed_warning)","rawText":"WARNING: BLEEDING RISK • Ticagrelor, like other antiplatelet agents, can cause significant, sometimes fatal bleeding ( 5.1 , 6.1 ). • Do not use ticagrelor tablets in patients with active pathological bleeding or a history of intracranial hemorrhage (4.1 , 4.2 ). •Do not start ticagrelor tablets in patients undergoing urgent coronary artery bypass graft surgery (CABG) ( 5.1 , 6.1 ). • If possible, manage bleeding without discontinuing ticagrelor tablets. Stopping ticagrelor tablets increases the","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:17:48.403940+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T01:18:00.154948+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Purinergic receptor P2Y12 negative allosteric modulator","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:17:59.226648+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL398435/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:17:59.132654+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA208541","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T01:17:48.403951+00:00"}},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:18:05.866513+00:00","fieldsConflicting":0,"overallConfidence":0.95},"crossReferences":{"chemblId":"CHEMBL398435"},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}